Seattle Children's Hospital (d/b/a Seattle Children's Research Institute)
发明人:
Michael A. Portman
申请号：
US16401698
公开号：
US20190336573A1
申请日:
2019.05.02
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present invention relates to the discovery that etanercept reduces the rate of resistance to intravenous gamma globulin (IVIG) in subjects with acute Kawasaki disease (KD). In certain embodiments, the co-administration of etanercept and IVIG more effectively treats acute KD in subjects older than 12 months than IVIG alone. In other embodiments, the co-administration of etanercept and IVIG ameliorates coronary artery dilation in high risk subjects.
